-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Immune Engaging Molecules in the Management of Lymphoid Malignancies

Program: Scientific Workshops @ ASH
Wednesday, December 2, 2020: 7:05 AM-8:20 AM
Moderators:
Disclosures:
Ansell: Bristol Myers Squibb: Research Funding; Seattle Genetics: Research Funding; Takeda: Research Funding; AI Therapeutics: Research Funding; Regeneron: Research Funding; Affimed: Research Funding; Trillium: Research Funding; ADC Therapeutics: Research Funding. Levy: Sutro: Membership on an entity's Board of Directors or advisory committees; Teneobio: Membership on an entity's Board of Directors or advisory committees; GigaGen: Membership on an entity's Board of Directors or advisory committees; Beigene: Membership on an entity's Board of Directors or advisory committees; Quadriga: Membership on an entity's Board of Directors or advisory committees; Checkmate: Membership on an entity's Board of Directors or advisory committees; Nurix: Membership on an entity's Board of Directors or advisory committees; Dragonfly: Membership on an entity's Board of Directors or advisory committees; Abpro: Membership on an entity's Board of Directors or advisory committees; Apexigen: Membership on an entity's Board of Directors or advisory committees; Spotlight: Membership on an entity's Board of Directors or advisory committees; 47 Inc.: Membership on an entity's Board of Directors or advisory committees; XCella: Membership on an entity's Board of Directors or advisory committees; Immunocore: Membership on an entity's Board of Directors or advisory committees; Walking Fish: Membership on an entity's Board of Directors or advisory committees; Viracta: Membership on an entity's Board of Directors or advisory committees.
Current Results with BITEs and Bispecific Antibodies in Lymphoid Malignancies

Max S. Topp, MD

Universitätsklinikum Würzburg, Würzburg, Germany
Live Q&A

Max S. Topp, MD

Universitätsklinikum Würzburg, Würzburg, Germany
BIKEs, TRIKEs, and SMITEs

Jeffrey S. Miller, MD

University of Minnesota, Minneapolis, MN
Live Q&A

Jeffrey S. Miller, MD

University of Minnesota, Minneapolis, MN
CD19 Antibodies and CD79-Directed ADCs in B-cell Malignancies

Laurie H. Sehn, MD, MPH

Centre for Lymphoid Cancer, Department of Medical Oncology, BC Cancer and The University of British Columbia, Vancouver, BC, Canada
Live Q&A

Laurie H. Sehn, MD, MPH

BC Cancer Centre for Lymphoid Cancer, University of British Columbia, vancouver, BC, Canada
See more of: Scientific Workshops @ ASH
<< Previous Session | Next Session >>